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Abstract 
Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle wasting disease. The disease is due 
to mutations in the DMD gene that encodes for a large intracellular protein called dystrophin. 
Dystrophin plays a critical role in linking the internal cytoskeleton of the striated muscle cell with the 
extracellular matrix as well as having cell signalling functions. In its absence muscle contraction is 
associated with cycles of damage, repair, inflammation and fibrosis with eventual loss of muscle and 
replacement with fat. Experiments in animal models of DMD have generated a number of different 
approaches to the induction of dystrophin including viral vector mediated delivery of a recombinant 
dystrophin gene, antisense oligonucleotide mediated exon-skipping to restore the open reading 
frame in the dystrophin mRNA, read-through of premature stop mutations, genome modification 
using CRISPR-Cas9 or cell based transfer of a functional dystrophin gene.  
In all cases, it will be important to understand how much dystrophin expression is required for a 
clinically effective therapy and this review examines the data from humans and animal models to 
estimate the percentage of endogenous dystrophin that is likely to have significant clinical benefit. 
While there are a number of important caveats to consider, including the appropriate outcome 
measures, this review suggests that approximately 20% of endogenous levels uniformly distributed 
within the skeletal muscles and the heart may be sufficient to largely prevent disease progression. 
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Introduction to Duchenne muscular dystrophy (DMD) 
Duchenne muscular dystrophy (DMD) is a fatal X-linked muscle wasting disorder characterised by 
repeated rounds of muscle degeneration, inflammation and repair. Over time, the inflammation 
leads to fibrosis, which in turn, possibly associated with satellite cell senescence, leads to a failure of 
regeneration and replacement of muscle with fat. Clinical signs include delayed motor milestones 
and using the arms to get up from the floor and to straighten the back (Gower’s manoeuvre). The 
gait becomes progressively stiffer and most boys become wheelchair dependent between 8 and 12 
years old. With good medical management, the average longevity is into the late 20’s although some 
patients live into their 40s. The most common causes of death are respiratory complications and 
cardiomyopathy, as also the heart is affected.  DMD occurs in 1 in 5,000 male births (Mendell et al., 
2012; Mah et al., 2014; Gatheridge et al., 2016) and is due to mutations in the DMD gene at position 
Xp21. A few unlucky girls with substantially skewed X-inactivation have clinical symptoms with the 
degree of skewedness correlating with disease severity (Pegoraro et al., 1995; Azofeifa et al., 1995). 
The DMD gene, isolated in 1986 (Koenig et al., 1987), is the largest known mammalian gene at 
2.4million base pairs long and encodes a 427kDa protein called dystrophin (Hoffman et al., 1987). 
Mutations associated with DMD come in all forms, deletions, duplications, nonsense and missense 
mutations but in almost all cases they lead to loss of the open reading frame and a premature stop 
codon. The gene has a high rate of spontaneous mutation and this accounts for over a third of cases. 
Consequently, there is a pressing unmet clinical need for novel therapies for this disease.  
There is an allelic condition, called Becker muscular dystrophy (BMD), where the mutation in the 
DMD gene does not disrupt the open reading frame. BMD patients produce an internally truncated 
dystrophin with intact amino and carboxyl termini. In general, BMD is a milder disease than DMD 
and in some cases BMD patients are asymptomatic (e.g. Melis et al., 1998; Ferreiro et al., 2009; 
Zimowski et al., 2017).  
Dystrophin has an amino terminal portion, which contains an actin-binding domain, 24 spectrin like 
repeat domains, four hinge regions, a cysteine rich domain and a carboxyl terminal portion. 
Dystrophin forms part of a link between the internal cytoskeleton of the striated muscle and the 
extracellular matrix. The amino domain binds to filamentous actin, whereas the cysteine rich domain 
binds to beta-dystroglycan, a membrane association protein that is bound to the highly glycosylated 
alpha dystroglycan that in turn binds to proteins in the extracellular matrix including the laminin 
alpha 2 chain of laminin 211. The carboxyl terminus of dystrophin interacts with a number of 
intracellular molecules including dystrobrevin and syntrophins that interact with cell signalling 
molecules such as neuronal nitric oxide synthase (nNOS). Dystrophin is essential for maintaining the 
integrity of striated muscle. When dystrophin is missing, the muscle is damaged during contractile 
activity.  
A wide range of potential therapies have been considered for DMD. They fall broadly into three 
categories. First is the induction of dystrophin in the striated muscles. The second is upregulation of 
other genes to replace dystrophin, focussed primarily on the autosomal homologue utrophin. The 
third strategy is to deal with the downstream consequences of the dystrophin deficiency: unstable 
membranes, accumulation of intracellular calcium, poor vascular perfusion, oxidative stress, 
nitrosylation of proteins, inflammation and fibrosis. This review focusses on the induction of 
dystrophin in striated muscle. 
 
Animal models of DMD 
A wide range of animal models have been discovered or generated for DMD. The best known is the 
dystrophic mdx mouse (Bulfield et al., 1984) that has a premature stop mutation in exon 23 of the 
murine DMD gene (Sicinski et al., 1989). Consequently, the mdx fails to produce dystrophin except in 
a small subset of fibres where idiosyncratic splicing leads to restoration of the open reading frame 
(revertant fibres). The mdx mouse has been the most widely used model of DMD with more than 
2,800 papers published and it is on the C57Bl10ScSn background. However, it is getting increasingly 
hard to access congenic control mice and so many investigators have used C57Bl6 controls. The mdx 
mouse is a good biochemical model of DMD but does not exhibit clear clinical signs of disease. 
Lifespan is only moderately reduced, the limb muscles show a hypertrophic response to muscle 
damage and only the diaphragm shows substantial fibrosis although other muscles show increased 
fibrosis in old age (e.g. Chamberlain et al., 2007). 
The original mdx has been backcrossed onto a variety of genetic backgrounds including BALB/cJ, 
C57BL/6J and FVB/Nj genetic backgrounds and these appear very similar to the original mdx mouse 
(McGreevy et al., 2015; Wasala et al., 2015). A backcross onto the DBA/2J appears to worsen the 
phenotype of the dystrophic mouse such as lower hind limb muscle weight, fewer myofibres, 
increased fibrosis and fat accumulation, and marked muscle weakness that may be the consequence 
of reduced regeneration following muscle damage (Fukada et al., 2010; Coley et al., 2016; Rodrigues 
et al., 2016; van Putten et al., 2019). Initial studies suggested that this cross also caused earlier 
cardiomyopathy but this pathology was observed also in the DBA/2J wild-type controls (Hakim et al., 
2017).  
A series of variants with mutations in different parts of the murine DMD gene were developed using 
N-ethylnitrosourea treatment of male mice and were termed mdx2cv, mdx3cv, and mdx4cv. (Chapman 
et al., 1989). Subsequently, the mdx5cv was also identified (Danko et al., 1992). These mice have all 
been backcrossed onto the C57Bl6 background. The mdx4cv and mdx5cv dystrophic mice have 
approximately 10-fold fewer revertants than the mdx mouse whereas the mdx3cv has a low level of 
full-length dystrophin expression (Danko et al., 1992). Another mouse mutant, lacking many of the 
smaller isoforms of dystrophin, has been generated by gene targeting, the mdx52 mouse (Araki et al., 
1997). 
In dystrophic mice utrophin, an autosomal homologue of dystrophin that preceeds dystrophin 
during skeletal muscle development (Helliwell et al., 1992), is upregulated in mature myofibres. 
Therefore, mdx mice were crossed with utrophin knockout mice to produce a mouse commonly 
referred to as the double knockout mouse, which has a more severe phenotype than the mdx mouse 
(Deconinck et al., 1997; Grady et al., 1997). While this mouse is arguably a better phenocopy of 
DMD, patients do not lack both dystrophin and utrophin. The mdx or mdxcv variants have also been 
crossed with a variety of other genetically manipulated mice to exacerbate the pathology. Because 
these mice show continued good regeneration, the mdx4cv has been crossed with a knockout for 
telomerase to produce the mdx4cv/mTR-/- mouse. This is a complex model as the loss of telomerase 
results in rapid ageing that increases with each generation. Second generation mdx4cv/mTR-/- mice 
show a skeletal muscle phenotype closer to DMD with a defect in muscle regenerative response 
(Sacco et al., 2010). Sialic acids are a class of cell-surface glycans that are involved in extracellular 
signalling. Mammals have two forms of sialic acids, Nacetylneuraminic acid (Neu5Ac) and N-
glycolylneuraminic acid (Neu5Gc). However, humans completely lack Neu5Gc. Thus, to “humanise” 
the mdx mouse, they were crossed with a mouse knockout for the enzyme that catalyzes the 
synthesis of Neu5Gc (Cmah-/-). Mdx/Cmah−/− mice were reported to show enhancement of DMD 
pathophysiology (Chandrasekharan et al., 2010) and show earlier cardiac pathophysiology than the 
standard mdx mice, although skeletal muscle physiology defects appeared less severe in a separate 
study (Betts et al., 2019). These and additional models are reviewed in more detail by Yucel and 
colleagues (2018). 
Dog models are also available, the most commonly used being a Golden Retriever with Muscular 
Dystrophy (GRMD), also known as CXMD, which has a splice site mutation that leads to the loss of 
exon 7 and thus a failure to produce dystrophin (Cooper et al., 1988; Sharp et al., 1992). Another dog 
model, this time with a splice site mutation leading to the loss of exon 50 is undergoing a natural 
history study at the Royal Veterinary College (London, UK) based on an index case identified in 2009 
(Walmsley et al., 2010). This latter dog model has been used to assess dystrophin levels arising from 
skipping of exon 51 using a CRISPR-Cas9 single cut strategy (Amoasii et al., 2018). New spontaneous 
mutations in the DMD gene continue to be recorded in dogs on a regular basis (e.g. Mata López et 
al., 2018; Nghiem et al., 2017). 
A number of other animal models have been developed but have not yet been used in published 
examples of dystrophin induction. These include dystrophic rats (Larcher et al., 2014; Nakamura et 
al., 2014), dystrophic cats (Gaschen et al., 1992), dystrophic rabbits (Sui et al., 2018) and dystrophic 
pigs (Klymiuk et al., 2013). The main features of these different animal models of DMD have been 
reviewed by Wells (2018). 
 
Induction of dystrophin 
Therapeutic induction of dystrophin expression potentially can be achieved by a number of different 
methods including viral vector mediated delivery of a recombinant dystrophin gene, antisense 
oligonucleotide mediated exon-skipping to restore the open reading frame in the dystrophin mRNA, 
read-through of premature stop mutations, genome modification using CRISPR-Cas9 or cell based 
transfer of a functional dystrophin gene. In all cases, it will be important to understand how much 
dystrophin expression is required for a clinically effective therapy. 
The use of viral vectors for gene therapy of DMD has been considered ever since the DMD gene was 
first reported. A number of systems were developed ranging from a heavily engineered version of 
adenovirus capable of accommodating the full coding sequence of the 11.5 kb dystrophin cDNA 
(Kochanek et al., 1996) through to small adeno-associated virus (AAV) only capable of 
accommodating 4.8 kb of exogenous DNA, thus requiring a compact promoter and a highly 
recombinant micro-dystrophin (Wang, Li and Xiao, 2000). Variants of the latter are currently in three 
human clinical trials (NCT03362502, NCT03368742 and NCT03375164). There is an excellent recent 
review by Duan (2018) of the development and use of AAV vectors to introduce recombinant 
microdystrophins into dystrophic muscle. In addition, a very recent paper by Ramos and colleagues 
(2019) has described problems with some of the existing microdystrophin constructs. The paper also 
suggests solutions for some of these problems. 
Another approach to induction of dystrophin is to use an antisense oligonucleotide (AO) to modulate 
splicing of the primary RNA transcript.  The AO is designed to either target exon recognition 
sequences or splice site sequences to prevent binding of the splicesosome and thus exclude one or 
more exons to restore the open reading frame in the dystrophin mRNA (exon-skipping). This 
approach, first published by the Dickson laboratory (Dunckley et al., 1998) and subsequently by 
other groups, was shown to be effective by inducing expression of dystrophin in murine and human 
cells in culture and in dystrophic mouse and dog models. Consequently, this approach was taken into 
human clinical trials using two different oligonucleotide chemistries. Both sets of trials targeted 
skipping of exon 51, as this would treat approximately 13% of DMD patients. One set of trials used a 
phosphorodiamidate morpholino oligomer (PMO) – eteplirsen - delivered via the intravenous route 
(Sarepta) and the other used a 2’OMethyl modified phosporothioate oligonucleotide (2OmePS) – 
drisapersen - delivered by the subcutaneous route (Prosensa / Biomarin). Drisapersen was rejected 
by the FDA on the basis of toxicity whereas eteplirsen was given accelerated approval in 2016 and is 
marketed as ExonDys51. In contrast, the European Medicines Agency did not approve eteplirsen. 
Approximately 13-15% of DMD patients have nonsense mutations that form a premature stop 
mutation. Aminoglycoside antibiotics have the ability to cause read-through these mutations, and 
this was demonstrated in the mdx mouse using gentamicin (Barton-Davies et al., 1999). 
Unfortunately, this was only achieved at high doses that have the potential to cause ototoxicity and 
nephrotoxicity and, although several small short clinical trials in DMD were subsequently 
undertaken, this was not a realistic long-term treatment for DMD. However, this observation 
inspired the search for small molecule drugs that could achieve the same effect with less toxicity and 
resulted in the identification of PTC124, also known as ataluren (Welch et al., 2007).  The efficacy 
and safety of ataluren were assessed in two randomised, double-blind, placebo-controlled, trials. 
Pre-specified subset analysis was considered sufficient for a conditional authorisation by the 
European Medicines Agency in 2014 and the drug is now marketed as Translarna. In contrast, the 
FDA did not approve Translarna. 
Another approach to inducing dystrophin is to perform genome editing, in most cases by using 
CRISPR-Cas9 technology. A series of papers were published in Science in 2016 reporting in vivo gene 
editing in the mdx mouse (Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016). 
Subsequently, issues relating to dose have been examined in long-term studies in the mdx mouse 
(Hakim et al., 2018) and one group has reported initial studies in a dystrophic dog model (Amoasii et 
al., 2018). The latter showed the potential for highly efficient gene editing but clinical application will 
require a greater understanding of the potential off-target effects with this technology (Nelson et al., 
2019). 
The final approach to induction of dystrophin utilises the ability of myoblasts to fuse with existing 
muscle fibres in both growth and repair. This enables cell based transfer of a functional dystrophin 
gene and was demonstrated by transferring congenic wild-type C57Bl10 myoblasts into the mdx 
mouse which resulted in good local levels of dystrophin (Partridge et al., 1989). This led to human 
clinical trials that were unsuccessful. Considerable effort was expended in testing potential stem cell 
therapies acting via myoblast fusion and one of the most promising, the use of mesoangioblasts 
(pericytes), led to a clinical trial which unfortunately failed to confirm the promising results in 
dystrophic mice and dogs (Cossu et al., 2015). 
 
Quantification of dystrophin 
In order to be able to predict the amount of dystrophin required for a clinically effective therapy it 
clearly will be important to understand the advantages and disadvantages of different methods of 
assessing the quantity of dystrophin protein. It is also important to understand whether the 
expression of dystrophin is patchy or uniform, as this may also influence the clinical effectiveness of 
any therapy that induces expression of dystrophin. Patchy expression can best be assessed by 
immunostaining, ideally calibrated against another membrane associated protein that does not 
change significantly with muscle pathology. Spectrin is commonly used when examining transverse 
sections of skeletal muscle, although it should be noted that spectrin expression is increased in 
dystrophic muscle. Whether this is the result of an increased number of small fibres or a genuine 
upregulation is unclear but clearly spectrin should be used with caution. A number of investigators 
have developed methods of quantifying the level of dystrophin expression in individual fibres in a 
section.  
The variation between quantitative immunohistochemistry and western blotting and between 
laboratories has been examined in a five laboratory study of a blinded sample set from BMD and 
DMD patients. After careful standardisation of the protocols, this study showed very similar 
quantification with minimal inter- and intra-laboratory variability (Anthony et al., 2014). This was 
particularly true of the quantitative immunohistochemistry and results from the quantitative 
immunohistochemistry closely matched those from western blot. Quantitative 
immunohistochemistry should cover the whole section and not just a region of interest. It is 
recommended that several different methods of quantification are used to increase confidence in 
the quantity of dystrophin detected. It is important that the same antibody is used to allow 
comparison of levels of dystrophin as different antibodies will have different affinities for 
dystrophin. 
Since then, additional refinements and novel technologies have been developed to improve the 
quantification of dystrophin. These include a new high throughput semi quantitative fluorescent 
immunofluorescence method for quantifying dystrophin expression in the whole of a transverse 
sections of skeletal muscle (Sardone et al., 2018) and the ProteinSimple capillary immunoassay 
(Wes) method, a gel- and blot-free method (Beekman et al., 2018). Another approach is to use mass 
spectroscopy of trypsin digests to quantify dystrophin. This approach was reported as having a lower 
detection limit of 5% of endogenous (Brown et al., 2012) but methods are in development with a 
lower detection limit of about 1% (see the following workshop report). 
Most recently, representatives of academia, patient organisations, industry and the United States 
Food and Drug Administration met in March 2018 to discuss the potential and problems of 
techniques currently used in translational research (western blot and immunofluorescence) and 
emerging techniques (mass spectrometry and capillary western immunoassay). The workshop 
concluded that it is now clear that dystrophin expression levels can vary considerably between 
healthy individuals and so there is a need for a primary reference standard for human clinical trials 
(Aartsma-Rus et al., 2019). 
 
Samples from patients 
Studies of patients with Duchenne and Becker muscular dystrophy have been used to assess the 
effects of low levels of dystrophin expression on clinical outcome. Early studies suggested that a 
delay in the loss of ambulation in DMD patients was due to low (trace) levels of dystrophin in 
otherwise dystrophic muscles (Nicholson et al., 1993) although this was in the absence of our 
current understanding about disease modifying genes in DMD (see for example Bello et al., 2016; 
Weiss et al., 2018). Dystrophin levels as low as 30% were reported as sufficient to prevent the 
development of muscular dystrophy in man (Neri et al., 2007). There are also several case reports of 
individual patients with no significant muscle impairment and low levels of dystrophin. For example, 
Nakamura and colleagues (2016) report a patient with a deletion of exons 3-9 and dystrophin 
protein expression 15% that of control level who had no muscle involvement at the age of 27 years 
old. While the above reports suggest that even low levels of dystrophin might be beneficial for 
patients, the quantification was based on muscle biopsies of a single muscle and so may not be 
representative of the body wide level of dystrophin in different muscles, yet clinical assessment is 
generally performed at the whole body level. 
The issue of problems quantifying the effects of treatment from single muscle biopsies is clearly 
outlined by studies in dystrophic mice. For example, both Alter and colleagues (2006) and Vila and 
co-workers (2015) have clearly shown that induction of dystrophin varies between muscles in mice 
systemically treated with antisense morpholino oligomers. 
Another caveat about patient studies is that internally truncated forms of the dystrophin protein, as 
seen in patients with Becker muscular dystrophy, may be substantially less functional that the 
normal full length isoform of dystrophin. A study by Anthony and colleagues (2011) examined 17 
BMD patients with a confirmed in-frame exon deletions equivalent to skipping of exons 51, 53 or 45–
55 multi-exon skipping in Duchenne muscular dystrophy. Patients in the model 51 group were either 
asymptomatic (three patients), or mildly affected (five patients). In the model 53 group, three 
patients were classified as mild; one asymptomatic and one severe; all four patients in the model 45-
55 group were classified as mild. All had levels of dystrophin 50% or more compared to normal 
controls. The authors concluded that “all varieties of internally deleted dystrophin assessed in this 
study have the functional capability to provide a substantial clinical benefit to patients with 
Duchenne muscular dystrophy”. However, modelling of different deletions has predicted substantial 
differences in the extent of disorganisation of the central rod domain of dystrophin (Delalande et al., 
2018) that might cause important differences in clinical benefit. 
 
 
Assessing the effects of different levels of dystrophin in animal models: 
A number of different outcome measures have been used to assess the response to treatment in 
animal models of muscular dystrophy. In order to ensure a degree of comparison between 
laboratories, a number of standard operating procedures (SOPs) have been developed with the 
animal model community (Grounds et al., 2008). These SOPs are currently available at the Treat-
NMD website (http://www.treat-nmd.eu/resources/research-resources/dmd-sops/).  
 
1. Histological and gene expression assays in the mouse 
Historically much has been made of changes in muscle pathology and gene expression. However, 
these are not in themselves a direct assessment of the functional result of dystrophin induction, but 
rather are an indirect assessment that can be misleading. SOPs exist on the above webpage for: 
Quantitative determination of muscle fibre diameter (minimal Feret’s diameter) and percentage of 
centralized nuclei (Treat-NMD SOP DMD_M.1.2.001); Quantification of histopathology in 
Haemotoxylin and Eosin stained muscle sections (Treat-NMD SOP DMD_M.1.2.007); and Serum 
Creatine Kinase analysis in mouse models of muscular dystrophy (Treat-NMD SOP MD_M.2.2.001). 
Changes in gene expression have been used to infer a functional benefit but some quantitative RT-
PCR studies are marred by the wrong choice of genes used to normalise the data. A comprehensive 
analysis of suitable housekeeping genes in normal and dystrophic mice of different ages and 
different muscles has recently been published (Hildyard et al., 2019). 
 
2. Conscious Functional assays in the mouse 
In order to assess the functional effects of treatment, a number of assays of the locomotor system 
have been developed for use in conscious mice. SOPs exist on the above webpage for: Behavioural 
and Locomotor Measurements Using Open Field Animal Activity Monitoring System (Treat-NMD SOP 
DMD_M.2.1.002); Use of treadmill and wheel exercise to assess dystrophic state (Treat-NMD SOP 
DMD_M.2.1.003); The use of hanging wire tests to monitor muscle strength and condition over time 
(Treat-NMD SOP DMD_M.2.1.004); Use of grip strength meter to assess the limb strength of mdx 
mice (Treat-NMD SOP DMD_M.2.2.001); and Whole body tension measurements (Treat-NMD SOP 
DMD_M.2.2.006). A potential problem with all of the above is that the performance of treated mice 
may vary with the central nervous system effects of the treatment. Activation of CNS centres or side-
effects such as nausea may give a misleading impression of the magnitude of the functional 
improvement. 
SOPs also exist for the assessment in conscious mice of the respiratory system (Treat-NMD SOP 
DMD_M.2.2.002) and the cardiovascular system (Treat-NMD SOP DMD_M.2.2.003). These are 
potentially less problematic than the locomotor system tests. There is also an SOP for cardiac 
assessment in anaesthetised mice (Treat-NMD SOP DMD_M.2.2.004). 
 
3. Muscle physiology in the mouse 
As an alternative to functional assessments in the conscious mouse, muscle physiology in the 
anaesthetised mouse or ex-vivo, measures changes in performance without the potential 
confounding effects of motivational state. Dystrophic muscle generates a lower specific force and is 
more vulnerable to eccentric (lengthening) contractions that wild-type muscle. An SOP has been 
developed for in situ measurement of muscle physiology in the lower hindlimb muscles (Treat-NMD 
SOP DMD_M.2.2.005). Alternatively, muscle physiology can be performed ex-vivo provided the 
muscles are small enough to ensure adequate perfusion to supply oxygen and substrate and to 
remove waste metabolites. Thus, this approach is suitable for small limb muscles such as the soleus 
and extensor digitorum longus muscles and for strips from the diaphragm. Again, an SOP is available 
(Treat-NMD SOP DMD_M.1.2.002). 
 
4. Assessments in the dystrophic dog 
As the dystrophic dogs show clear clinical signs of muscular dystrophy, in contrast to dystrophic 
mice, there are a number of functional tests that can be applied in the conscious animal, such as gait 
measures. It is also possible to do similar muscle physiology tests but as non-terminal anaesthetised 
procedures with needle electrodes and measuring torque using a pedal (Childers et al., 2002; Treat-
NMD SOP DMD_D.2.2.001). The response to eccentric exercise can also be measured using a similar 
approach (Treat-NMD SOP DMD_D.2.2.002). 
 
Effects of different levels of dystrophin in mouse models. 
The mdx3cv mouse shows low levels of full-length dystrophin, estimated at 5% of wild-type levels, 
and this is associated with higher muscle forces, and a reduced force drop associated with eccentric 
exercise, despite dystrophic pathology similar to the mdx4cv mouse (Li et al., 2008). The same strain 
showed a reduced muscle stiffness compared to the mdx4cv mouse (Hakim and Duan, 2012). 
Similarly, the same low level uniform expression of dystrophin in the mdx3cv mouse also partially 
preserved heart function compared to the mdx4cv mouse (Wasala et al., 2017). The same level of 
dystrophin also ameliorated the pathology and increased the lifespan in the double knockout mouse 
when the utrophin knockout mouse was crossed with the mdx3cv mouse (Li et al., 2010). 
A number of studies have reported the effects of restoring different levels of dystrophin in the mdx 
mouse. 20% of normal levels of dystrophin induced by treatment with high doses of gentamicin 
significantly reduced the force deficit associated with eccentric exercise when compared to 
untreated mdx mice (Barton-Davis et al., 1999). 
Sharp and colleagues (2011) examined the functional effects of exon-skipping arising from increasing 
intramuscular doses of the M23D phosphorodiamidate morpholino oligomer (PMO) sequence that 
was originally developed by Gebski and colleagues (2003). They showed a good correlation between 
the percentage of dystrophin positive fibres and the induction of dystrophin and that this also 
correlated with the reduction in force drop following eccentric exercise. They concluded that a 
minimum of 20% of dystrophin-positive fibers is required for any meaningful improvement in muscle 
physiology. 
Godfrey and colleagues (2015) examined the functional consequences of inducing dystrophin 
expression using a cell penetrating peptide (Pip6a) coupled to the M23D PMO. They concluded that 
15% of normal levels of dystrophin were sufficient to prevent the force drop associated with 
eccentric exercise in the tibialis anterior muscle of terminally anaesthetised mdx mice. Further 
studies performed in the Wells laboratory (in preparation) using a lower dose of Pip6aPMO confirm 
that expression of 15% of endogenous levels of dystrophin following chronic dosing studies is indeed 
sufficient to prevent the force drop associated with eccentric contractions and that lower levels offer 
some reduction in the force drop. 
The Aartsma-Rus laboratory have developed a mouse model expressing low dystrophin levels, based 
on non-random X-inactivation. They crossed the mdx mouse with a transgenic mouse that shows a 
skewed X-inactivation (Xisths) that generates mice with a range of different levels of dystrophin (van 
Putten et al., 2012). They have used these mice to examine the effects of different levels of 
dystrophin on locomotor performance and response to chronic exercise. The 2012 study concluded 
that “while even dystrophin levels below 15% can improve pathology and performance, levels of 
>20% are needed to fully protect muscle fibers from exercise-induced damage”. They have 
subsequently used the same model system to look at the effects of low levels of dystrophin on 
slowing the development of heart failure in the mdx-Xisths mice (van Putten et al., 2014) but failing 
to normalize the neuromuscular synaptic abnormalities of mdx-Xisths mice (van der Pijl et al., 2018). 
The same strategy was used in the dystrophin/utrophin double knockout mice with low levels of 
dystrophin increasing survival and improving muscle pathology and function (van Putten et al., 
2013). However, it is not possible to directly compare the results from the mdx-Xisths studies with 
those in the mdx3CV mice and the Pip6aPMO studies as in the latter two examples there was fairly 
uniform expression of dystrophin between muscle fibres whereas the mdx-Xisths mice show a 
mosaic pattern of dystrophin expression within and between muscle fibres. In contrast, the patchy 
expression in the mdx-  mice may be a good model of a less than optimal response to gene 
therapy. It should also be noted that the mdx-Xisths and the mdx3CV mice have expressed dystrophin 
prior to the onset of the 3 week necrotic phase seen in the mdx mouse, whereas the Pip6aPMO 
studies were conducted in adult mdx mice that had already developed muscular dystrophy.  
 
Effects of different levels of dystrophin in dog models. 
There are relatively few studies of induced dystrophin expression in dystrophic dogs. While recent 
studies such as (Yue et al., 2015; Le Guiner et al., 2017) show the effectiveness of systemic delivery 
in the GRMD model, they do not allow a quantification of the minimum levels of dystrophin required 
for clinical benefit. Le Guiner and colleagues (2014) used rAAV8-U7snRNA to promote permanent 
exon-skipping by locoregional delivery to the forelimb in GRMD. They determined a minimum 
threshold of dystrophin expressing fibres (>33% for structural measures and >40% for strength) 
under which there was no clear-cut therapeutic effect.  Gentil and colleagues (2016) examined some 
of the same samples and compared the percentage of dystrophin-positive fibres with western blots 
of key proteins such as neuronal nitric oxide synthase mu (nNOSμ), inducible nitric oxide synthase 
(iNOS), and ryanodine receptor-calcium release channel type 1 (RyR1). They concluded that 40% of 
the fibres need to be dystrophin positive for normalisation. Neither of the two locoregional 
perfusion studies measured the quantity of dystrophin in the positive fibres. Thus, to date we really 
have no measure of the minimum amount of dystrophin required to be therapeutic in the dog. 
 
Conclusions  
A number of different strategies have been developed to restore dystrophin expression in skeletal 
and cardiac muscles and a wide range of animal models of DMD are available for testing these 
strategies. To date, the majority of such studies have been conducted in dystrophic mice and dogs. 
Data from man and animal models shows that any increase in dystrophin is likely to have some 
benefit and the more dystrophin the better. It is more difficult to assign a minimal level of 
dystrophin expression required for effective therapy of DMD. The most promising of the current 
strategies for induction of dystrophin result in an internally truncated dystrophin protein, which may 
have different properties from the normal full-length isoform. There are likely to be differences in 
the amount of dystrophin required to prevent the development of muscular dystrophy compared to 
that required to address existing disease. In the case of existing disease, there may well be 
differences between animal models and man, particularly in the case of the mdx mouse that 
manifests a relatively mild version of the disease and shows limited fibrosis compared to humans 
with DMD. The amount of dystrophin required is likely to vary with the stage of disease progression. 
Finally, the longevity of the treatment effect is also likely to be dependent on the level of dystrophin 
expression achieved and the uniformity of this expression both within and between individual 
myofibres or cardiomyocytes. 
As a working hypothesis, it would appear that about 20% of normal levels of a functional version of 
recombinant dystrophin with a uniform expression is likely to be sufficient to essentially stop disease 
progression and thus offer major clinical benefit for DMD patients. 
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